Eupraxia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPRX research report →
Range $11 – $25
Price Chart
About the company
Eupraxia Pharmaceuticals Inc. , a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
- CEO
- James A. Helliwell
- IPO
- 2024
- Employees
- 49
- HQ
- Victoria, BC, CA
Get TickerSpark's AI analysis on EPRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $259.14M
- P/E
- -7.58
- PEG
- 0.34
- P/S
- 0.00
- P/B
- 3.91
- EV/EBITDA
- -4.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -45.29%
- ROIC
- -43.07%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-38,434,039
- Net Income
- $-38,576,143-51.3%
- EPS
- $-1.03-35.5%
- OCF Growth
- +3.2%
- FCF Growth
- +1.6%
- 52W High
- $9.32
- 52W Low
- $5.25
- 50D MA
- $7.36
- 200D MA
- $7.34
- Beta
- 1.50
- RSI (14)
- 48
- Avg Volume
- 541.26K
No earnings-call transcripts are available for EPRX yet.
- Free Float
- 77.2%
- Shares Outstanding
- 33.48M
- Float Shares
- 25.83M
of shares held by institutions
55 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Beutel, Goodman & Co Ltd. | 3.63M | ▼ 38.60K |
| Affinity Asset Advisors, LLC | 1.65M | ▲ 60.99K |
| Balyasny Asset Management L.P. | 1.35M | ▲ 15 |
| Vivo Capital, LLC | 1.35M | 0 |
| Scotia Capital Inc. | 1.34M | ▲ 1.55K |
| Pfm Health Sciences, LP | 1.21M | ▲ 669.79K |
| Great Point Partners LLC | 1.20M | 0 |
| Jupiter Topco LLC | 1.05M | ▲ 1.05M |
| Rubric Capital Management LP | 867.42K | ▲ 176.25K |
| Ikarian Capital, LLC | 809.74K | ▼ 405.00K |
| Woodline Partners LP | 746.86K | ▲ 306.31K |
| Point72 Asset Management, L.P. | 730.28K | ▼ 237.29K |
Our EPRX coverage
Recent articles, reports, and earnings notes.
No research on EPRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPRX report →Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
globenewswire.com · Sep 30
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
globenewswire.com · Sep 8
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
globenewswire.com · Aug 13
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 11
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?
zacks.com · Aug 10
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Moderate Buy” by Brokerages
defenseworld.net · Aug 3
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
globenewswire.com · Jul 13
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
globenewswire.com · Jul 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.